Jefferies Group LLC Vaxart, Inc. Transaction History

Jefferies Group LLC

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 15, 2022	SELL	$2.7 - $5.28 $34,074 - $66,633	-12,620 Closed	0 $0
Q1 2022 May 16, 2022	SELL	$4.29 - $6.64 $81,561 - $126,239	-19,012 Reduced 60.1%	12,620 $1,000
Q4 2021 Feb 14, 2022	BUY	$5.77 - $7.96 $182,516 - $251,790	31,632 New	31,632 $79,000
Q2 2021 Aug 16, 2021	SELL	$5.06 - $10.78 $541 - $1,153	-107 Closed	0 $0
Q1 2021 Sep 21, 2023	SELL	$5.64 - $23.33 $1.27 Million - $5.25 Million	-224,893 Reduced 99.95%	107 $0
Q1 2021 May 14, 2021	SELL	$5.64 - $23.33 $1.27 Million - $5.25 Million	-224,893 Reduced 99.95%	107 $1,000
Q4 2020 Sep 21, 2023	BUY	$3.5 - $7.98 $787,500 - $1.8 Million	225,000 New	225,000 $1.28 Million
Q4 2020 Feb 16, 2021	BUY	$3.5 - $7.98 $787,500 - $1.8 Million	225,000 New	225,000 $1.29 Million

107

37.7M

188K

180K

Ticker VXRT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 126,506,000
Market Cap $86M
Description
Vaxart, Inc., a clinical-stage biotechnology company, engages in the discovery and development of oral recombinant protein vaccines based on its proprietary oral vaccine platform. The company's product pipeline includes norovirus vaccine, an oral tablet vaccine, which is in a Phase Ib clinical trial with bivalent oral tablet vaccine for the GI.1...

Get notified when there are updates to the investment portfolio of Jefferies Group LLC, based on Form 13F filings with the SEC.

Stay updated on Jefferies Group LLC with notifications on news.